kc1036
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04387916)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
KDR inhibitor
FLT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06564272 | Phase 2 | Sep 27, 2024 | Beijing Konruns Pharmaceutical Co., Ltd., Capital Medical University |
| NCT06194734 | Phase 3 | Feb 5, 2024 | Beijing Konruns Pharmaceutical Co., Ltd., Chinese Academy of Medical Sciences |
| NCT05683886 | Phase 2 | Feb 22, 2023 | Beijing Konruns Pharmaceutical Co., Ltd., Jiao Tong University, Sichuan University |
| NCT05260385 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2022 | Beijing Konruns Pharmaceutical Co., Ltd. |
| NCT05265338 | N/A | Feb 16, 2022 | Beijing Konruns Pharmaceutical Co., Ltd. |
| NCT04387916 | Phase 1 | Jul 31, 2020 | Beijing Konruns Pharmaceutical Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Konruns Pharmaceutical Co., Ltd. | For profit | 6 | 6 | 4 | 2020 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1